Automated Insulin Delivery and Monitoring System for Younger Pediatric Patients Approved by FDA

Author: U.S. Food and Drug Administration (FDA)
Published: 2018/06/21 - Updated: 2019/02/08
Peer-Reviewed: N/A
Contents: Summary - Main - Related Publications

Synopsis: FDA approval of MiniMed 670G hybrid closed looped diabetes device to automatically monitor glucose and provide appropriate basal insulin doses for individuals aged 7 to 13 with type 1 diabetes.

The U.S. Food and Drug Administration today expanded the approval of the MiniMed 670G hybrid closed looped system, a diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from the user, to include individuals aged 7 to 13 with type 1 diabetes.

Main Digest

The U.S. Food and Drug Administration today expanded the approval of the MiniMed 670G hybrid closed looped system, a diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from the user, to include individuals aged 7 to 13 with type 1 diabetes.

The FDA originally approved this device in September 2017 for use in patients 14 years of age and older with type 1 diabetes.

"Type 1 diabetes is a life-threatening chronic condition requiring continuous and life-long management that can be stressful for patients and their caregivers, especially when the patients are young children," said FDA Commissioner Scott Gottlieb, M.D.

"Caregivers and families of young patients with diabetes face unique challenges in managing this disease, in particular the round-the-clock glucose monitoring that can be disruptive to people's lives. Advances in science, technology and manufacturing are contributing to the development of new and expanded uses of products that can help improve the quality of life for those with chronic diseases, especially vulnerable populations, like children. Today we're extending these opportunities to younger children who are especially vulnerable to the impact of this disease, such as the disruptions in sleep that can be caused by the need for frequent blood glucose checks. The FDA is dedicated to promoting policies that support the development of new technologies based on these advances, and to ensuring that the path to market is both efficient and effective."

The human pancreas naturally supplies a low, continuous rate of insulin, known as basal or background insulin.

In patients with diabetes, the body's ability to produce or respond to insulin is impaired. Because the pancreas does not make insulin in people with type 1 diabetes, patients must consistently monitor their glucose levels throughout the day and inject insulin with a syringe, pen or pump to avoid becoming hyperglycemic (high glucose levels). In addition, management of type 1 diabetes includes following a healthy eating plan and physical activity. Type 1 diabetes, also known as juvenile diabetes, is typically diagnosed in children and young adults.

The MiniMed 670G hybrid closed looped system works by measuring glucose levels in the body every five minutes and automatically adjusting insulin delivery by either administering or withholding insulin.

The system includes:

While the device automatically adjusts insulin levels, users need to manually request insulin doses to counter carbohydrate consumption at mealtime.

The FDA evaluated data from a clinical trial of the MiniMed 670G hybrid closed looped system that included 105 individuals aged 7 to 11 years old.

Study participants wore the device for approximately 3.5 months and participated in three phases of the study to evaluate both at-home use as well as remote use. That study found no serious adverse events associated with use of the MiniMed 670G and that the device is safe for use in people age 7 to 13 years with type 1 diabetes.

Risks associated with use of the system may include hypoglycemia, hyperglycemia, as well as skin irritation or redness around the device's infusion patch.

As part of this approval, the FDA is requiring the product developer to conduct a post-market study to evaluate device performance in real-world settings in children between the ages of 7 and 13. This device is not approved for use in children 6 years of age or younger and in individuals who require less than eight units of insulin per day.

The expanded approval of MiniMed 670G hybrid closed looped system was granted to Medtronic.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Attribution/Source(s):

This quality-reviewed publication pertaining to our FDA News and Approvals section was selected for circulation by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "Automated Insulin Delivery and Monitoring System for Younger Pediatric Patients Approved by FDA" was originally written by U.S. Food and Drug Administration (FDA), and submitted for publishing on 2018/06/21 (Edit Update: 2019/02/08). Should you require further information or clarification, U.S. Food and Drug Administration (FDA) can be contacted at the fda.gov website. Disabled World makes no warranties or representations in connection therewith.

📢 Discover Related Topics


👍 Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/fda/minimed-670g.php">Automated Insulin Delivery and Monitoring System for Younger Pediatric Patients Approved by FDA</a>

Cite This Page (APA): U.S. Food and Drug Administration (FDA). (2018, June 21). Automated Insulin Delivery and Monitoring System for Younger Pediatric Patients Approved by FDA. Disabled World. Retrieved February 24, 2024 from www.disabled-world.com/medical/pharmaceutical/fda/minimed-670g.php

Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.